BRIEF-Pharming Group Q1 Revenue Down to USD 42.5 Mln

Reuters · 05/11/2023 01:26
BRIEF-Pharming Group Q1 Revenue Down to USD 42.5 Mln

- Pharming Group NV PHAR.AS:

  • PHARMING GROUP REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2023

  • Q1 REVENUE FELL 9 PERCENT TO $42.5 MILLION

  • FDA APPROVAL AND COMMERCIAL LAUNCH OF JOENJA® (LENIOLISIB) IN U.S.

  • JOENJA® LAUNCH OFF TO STRONG START WITH 23 U.S. PATIENTS ON PAID THERAPY

  • REVENUES DECREASED BY 9% TO US$42.5 MILLION, COMPARED TO Q1 OF 2022

  • CONTINUE TO ANTICIPATE LOW SINGLE DIGIT GROWTH IN ANNUAL REVENUES FROM RUCONEST® IN 2023

  • CONTINUED SIGNIFICANT INVESTMENTS MADE IN LENIOLISIB LAUNCH PREPARATIONS AND ORGANIZATIONAL STRUCTURE

  • OVERALL CASH BALANCE OF US$184.8 MILLION AT END OF QUARTER

Source text for Eikon: ID:

Further company coverage: PHAR.AS


(Gdansk Newsroom)

((gdansk.@thomsonreuters.com ; +48 58 769 66 00;))